Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-26T13:19:48.943Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls

Published online by Cambridge University Press:  16 April 2020

N. Goto ,
R. Yoshimura ,
S. Kakeda ,
J. Moriya ,
K. Hayashi ,
A. Ikenouchi-Sugita ,
W. Umene-Nakano ,
H. Hori ,
N. Ueda  and
Y. Korogi
...Show all authors
N. Goto
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
R. Yoshimura*
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
S. Kakeda
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
J. Moriya
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
K. Hayashi
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
A. Ikenouchi-Sugita
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
W. Umene-Nakano
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
H. Hori
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
N. Ueda
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
Y. Korogi
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
J. Nakamura
Affiliation:
Department of Psychiatry and Radiology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Japan
*
*Corresponding author. Tel.: +8 19 36 91 72 53; fax: +8 19 36 92 48 94. E-mail address: [email protected] (R. Yoshimura).
Get access

Abstract:

Background:

N-acetylaspartate (NAA) levels and serum brain-derived neurotrophic factor (BDNF) levels in patients with first-episode schizophrenia psychosis and age- and sex-matched healthy control subjects were investigated. In addition, plasma levels of homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were compared between the two groups.

Method:

Eighteen patients (nine males, nine females; age range: 13–52 years) were enrolled in the study, and 18 volunteers (nine males, nine females; age range: 15–49 years) with no current or past psychiatric history were also studied by magnetic resonance spectroscopy (MRS) as sex- and age-matched controls.

Results:

Levels of NAA/Cr in the left basal ganglia (p = 0.0065) and parieto-occipital lobe (p = 0.00498), but not in the frontal lobe, were significantly lower in patients with first-episode schizophrenia psychosis than in control subjects. No difference was observed between the serum BDNF levels of patients with first-episode schizophrenia psychosis and control subjects. In regard to the plasma levels of catecholamine metabolites, plasma MHPG, but not HVA, was significantly lower in the patients with first-episode psychosis than in control subjects. In addition, a significantly positive correlation was observed between the levels of NAA/Cr of the left basal ganglia and plasma MHPG in all subjects.

Conclusions:

These results suggest that brain NAA levels in the left basal ganglia and plasma MHPG levels were significantly reduced at the first episode of schizophrenia psychosis, indicating that neurodegeneration via noradrenergic neurons might be associated with the initial progression of the disease.

Keywords

SchizophreniaN-acetylaspartateBrain-derived neurotrophic factor3-methoxy-4-hydroxyphenylglycolHomovanillic acid
Type
Original article
Information
European Psychiatry , Volume 26 , Issue 1 , January 2011 , pp. 57 - 63
Copyright
Copyright © Elsevier Masson SAS 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altar, CACai, NBliven, TJuhasz, MConner, JMAcheson, AKet al.Antegrade transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856–860.CrossRefGoogle Scholar
Bartfai, AEdman, GLevander, SESchalling, DSedvall, GBilateral skin conductance activity, clinical symptoms and CSF monoamine metabolite levels in unmedicated schizophrenics, differing in rate of habituation. Biol Psychiatry 1984; 18: 201–218.CrossRefGoogle ScholarPubMed
Bartha, RWilliamson, PCDrost, DJMalla, MCarr, TCortese, Let al.Measurement of glutamate and glutamine in the medial prefrontal cortex of never treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959–965.CrossRefGoogle ScholarPubMed
Bertolino, ACallicott, JHElman, IMattay, VSTeschedi, GFrank, JAet al.Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998; 43: 641–648.CrossRefGoogle ScholarPubMed
Buckley, PFPillai, AEvans, DStirewalt, EMahadik, SBrain derived neurotrophic factor in first-episode psychosis. Schizophr Res 2007; 91: 1–5.CrossRefGoogle ScholarPubMed
Bustillo, JRLauriello, JRowland, LMThomson, LMPetropoulos, HHammond, Ret al.Longitudinal follow-up neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 2002; 58: 313–321.CrossRefGoogle ScholarPubMed
Bustillo, JRRowland, LMJung, RBrooks, WMQualls, CHammond, Ret al.Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacol 2008; 33: 2456–2466.CrossRefGoogle Scholar
Cecil, KMLenkinski, REGur, REGur, RCProton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 1999; 20: 131–140.CrossRefGoogle ScholarPubMed
Choe, BYSuh, TSShinn, KSLee, CWPaik, LHObservation metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Inv Radiol 1999; 31: 345–352.CrossRefGoogle Scholar
Coupland, NJOgilvie, CJHegadoren, KMSeres, PHanstock, CCAllen, PSDecreased prefrontal myoinositol in major depressive disorder. Biol Psychiatry 2005; 57: 1526–1534.CrossRefGoogle ScholarPubMed
Durany, NMichel, TZochling, RBoissl, KWCruz-Sanchez, FFRiederer, Pet al.Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79–86.CrossRefGoogle ScholarPubMed
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured clinical interview for DSM-IV axis I disorders, Patient edition (SCID-P), version 2. New York State Psychiatric Institute, Biometrics Research, New York; 1995..CrossRefGoogle Scholar
Gama, CSAndreazza, ACKunz, MBerk, MBelmonte-de-Abreu, PSKapczinski, FSerum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007; 420: 45–48.CrossRefGoogle ScholarPubMed
Goto, N, Yoshimura, R, Moriya, J, Kakeda, S, Ueda, N, Ikenouchi-Sugita, A, et al. Reduced brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 2009;112:192–3 (Epub ahead of print)..CrossRefGoogle Scholar
Grillo, RWOttoni, GLeke, RSouza, DOPortela, LVLara, DRReduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41: 31–35.CrossRefGoogle ScholarPubMed
Guillain, ODiaz, JCarroll, PGriffon, NSchwartz, JCSokoloff, PBDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 2001; 411: 86–89.CrossRefGoogle Scholar
Hori, HYoshimura, RYamada, YIkenouchi, AMitoma, MIda, Yet al.Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007; 22: 21–27.Google ScholarPubMed
Jessen, FScherk, HTraber, FTheyson, SBerning, JTepest, Ret al.Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res 2006; 87: 81–88.CrossRefGoogle ScholarPubMed
Kay, SRFiszbein, AOpler, LAThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.CrossRefGoogle Scholar
Lauder, JMKrebs, HDo neurotransmitters, neurotumors and hormones specify critical periods? In: Greenough, WTJuraska, JM editors. Developmental Neuropsychobiology. Orland, FL: Academic Press; 1986. p. 119–174.Google Scholar
Lieberman, JAKoreen, ARNeurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19: 371–429.CrossRefGoogle ScholarPubMed
Lu, ZHChakraborty, GLedeen, RWYahya, DWu, GN-acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Brain Res Mol Brain Res 2004; 122: 71–78.CrossRefGoogle ScholarPubMed
Mescher, MMerkle, HKirsh, JGarwood, MGruetter, MSimultaneous in vivo spectral editing and water suppression. NMR Biomed 1998; 11: 266–272.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Minegishi, AIshizaki, TDetermination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr 1984; 311: 51–57.CrossRefGoogle ScholarPubMed
Nyback, HBerggren, BMHindmarsh, TSedvall, GWiesel, FACerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 1983; 9: 301–308.CrossRefGoogle ScholarPubMed
Ohmann, PSiegmund, ASuslow, TPedersen, ASpizberg, KKersting, Aet al.Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic medicated resonance spectroscopy study. J Psychiatr Res 2007; 41: 625–634.CrossRefGoogle Scholar
Pirildar, SGonul, ASTaneli, FAkdeniz, FLow serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 709–713.CrossRefGoogle Scholar
Provenhcar, SWEstimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672–679.CrossRefGoogle Scholar
Ren, ZGPorzgen, PPYoun, YHSieber-Blum, MUbiquitious embryonic expression of the norepinephrine transporter. Dev Neurosci 2003; 25: 1–13.CrossRefGoogle Scholar
Shimizu, EHashimoto, KWatanabe, HKomatsu, NOkamura, NKoike, Ket al.Serum brain-drived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003; 351: 111–114.CrossRefGoogle Scholar
Stanley, JAWilliamson, PCDrost, DJRylett, RJCarr, TJMalla, Aet al.An in vivo proton magnetic resonance spectroscopy study of schizophrenic patients. Schizophr Bull 1996; 22: 597–609.CrossRefGoogle Scholar
Steen, RGHamer, RMLieberman, JAMeasurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949–1962.CrossRefGoogle ScholarPubMed
Takahashi, MShirakawa, OToyooka, KKitamura, NHashimoto, TMaeda, Ket al.Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293–300.CrossRefGoogle ScholarPubMed
Tan, YLZhou, DFCao, LYZhang, XYDecreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005; 382: 27–32.CrossRefGoogle ScholarPubMed
Thoenen, HNeurotrophins and neural plasticity. Science 1995; 270: 593–598.CrossRefGoogle Scholar
Toyooka, KAsama, KWatanabe, YMuratake, TTakahashi, MSomeya, Tet al.Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110: 249–257.CrossRefGoogle ScholarPubMed
Van Kammen, DPGelerter, JBiochemical instability in schizophrenia: I The norepinephrine system. In: Meltzer, HY editors. Psychopharmacology 3rd generation. New York: Raven Press; 1987. p. 745–751.Google Scholar
Weickert, CSWeinberger, DRA candidate molecular approach defining development pathology in schizophrenia. Schizophr Bull 1998; 24: 303–316.CrossRefGoogle Scholar
Weickert, CSHyde, TMLipska, BKHermann, MMWeinberger, DRKleinman, JEReduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003; 8: 592–610.CrossRefGoogle ScholarPubMed
Weickert, CSLigons, DLRomanzyk, TUngaro, GHyde, TMHerman, MMet al.Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005; 10: 637–650.CrossRefGoogle ScholarPubMed
Wood, SJBerger, GEWellard, RMProffitt, TMMcConchie, MBerk, Met al.Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009; 33: 354–357.CrossRefGoogle ScholarPubMed
Yamamoto, KHornykiewicz, OProposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 913–922.CrossRefGoogle ScholarPubMed
Yeung, PKFBuckley, SJPedder, SCJDingemanse, JDetermination of 3,4-dihydroxyphenylphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 1996; 85: 451–453.CrossRefGoogle ScholarPubMed
Yoshimura, RHori, HSugita, AUeda, NKakihara, SUmene, Wet al.Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1072–1077.CrossRefGoogle Scholar
Yoshimura, R, Ueda, N, Hori, H, Ikenouchi-Sugita, A, Umene-Nakano, W, Nakamura, J. Differential patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-drived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2008;2:1–6 (Epub ahead of print)..CrossRefGoogle Scholar
Yoshimura, RYanagihara, NHara, KTerao, TNakamura, JUeno, Set al.Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells. Psychopharmacology 2000; 149: 17–23.CrossRefGoogle ScholarPubMed
Yoshimura, RNakamura, JUeda, NTerao, TEffect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol(pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels and clinical improvement. Int Clin Psychopharmacol 2000; 15: 175–180.CrossRefGoogle ScholarPubMed
Yoshimura, RYanagihara, NHara, KNakamura, JToyohira, YUeno, Set al.Dual phase of functional change in norepinephrine transporter in cultured bovine adrenal medullary cells by long-term treatment with clozapine. J Neurochem 2001; 77: 1018–1026.CrossRefGoogle ScholarPubMed
Yoshimura, RShinkai, KToyohira, YUeno, SYanagihara, NNakamura, JEffects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. Hum Psychopharmacol 2005; 20: 477–484.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.